What is QV Bioelectronics?
QV Bioelectronics is a pioneering medical technology firm dedicated to the development of implantable bioelectronic devices designed to combat aggressive cancers, with a primary focus on brain tumors. The company's core technology utilizes targeted electric field therapy to disrupt the division of cancer cells while preserving the integrity of surrounding healthy tissue. This approach represents a significant shift from conventional systemic treatments, offering a localized solution that integrates seamlessly with existing surgical and oncology protocols. By bridging the gap between deep-tech innovation and patient-centric care, the company is addressing critical unmet needs in the oncology sector.
How much funding has QV Bioelectronics raised?
QV Bioelectronics has raised a total of $7.8M across 2 funding rounds:
Other Financing Round
$2.5M
Grant
$5.4M
Other Financing Round (2023): $2.5M with participation from Fink Family Law Offices, Science Angel Syndicate, Northern Gritstone, and Catapult Ventures
Grant (2026): $5.4M led by UK Research & Innovation, GM&C Life Sciences Fund, NIHR, and Empirical Ventures
Key Investors in QV Bioelectronics
Empirical Ventures
A specialist venture capital firm focused on investing in Europe's early-stage, deep-tech ventures, with a strong emphasis on Life Sciences and TechBio.
GM&C Life Sciences Fund
A venture capital firm that focuses on seed and early-stage investments in life sciences and growth opportunities across the UK.
Northern Gritstone
An investment company dedicated to supporting science and technology businesses in the North of England with a philosophy of profit with purpose.
What's next for QV Bioelectronics?
With the recent influx of capital, QV Bioelectronics is well-positioned to accelerate its clinical development and operational scaling. The strategic focus will likely shift toward expanding its research capabilities and refining its implantable device architecture to meet regulatory milestones. As the company moves deeper into its lifecycle, the emphasis will remain on validating the efficacy of its electric field therapy in broader clinical settings. The backing from specialized life sciences investors suggests a robust roadmap for commercialization, with the potential to transform standard-of-care practices for patients facing aggressive malignancies. Future growth will be defined by the company's ability to translate its technological breakthroughs into scalable, high-impact clinical outcomes.
See full QV Bioelectronics company page
